Adalimumab is primarily used in the treatment of autoimmune diseases. It is effective in managing conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis. By targeting and neutralizing tumor necrosis factor-alpha (TNF-α), it helps reduce inflammation and slow disease progression. This medication is often prescribed when other treatments have not provided adequate relief. It is administered via subcutaneous injection and requires regular monitoring to manage potential side effects and ensure therapeutic efficacy.